Navigation Links
Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011
Date:5/16/2011

INDIANAPOLIS, May 16, 2011 /PRNewswire/ -- Data on nine Lilly Oncology molecules in development will be presented during the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. from June 3 – 7, 2011.  Lilly Oncology's pipeline is one of the largest in the industry, with more than 30 molecules in development to treat various types of cancer.  

Nearly all of these pipeline molecules are being evaluated for certain biomarkers or genetic mutations that can help researchers identify which patients are most likely to respond to these medicines, and as importantly, which are not.  

At ASCO, Lilly will present Phase II data on two fully human IgG1 monoclonal antibodies: cixutumumab for the treatment of patients with advanced or metastatic soft tissue sarcoma and Ewing family of tumors; and ramucirumab for the treatment of locally advanced or metastatic breast cancer.  Lilly will also present data on a Phase I study of LY2127399, a human anti-BAFF antibody for patients with previously-treated multiple myeloma.  Additionally, Lilly will present data from several studies of enzastaurin, a selective serine-threonine kinase inhibitor that targets the PKC Beta and PI3/AKT pathways.

"Lilly is very much in alignment with this year's ASCO conference theme, 'Patients, Pathways, Progress,'" said Richard Gaynor, M.D., vice president, product development and medical affairs for Lilly Oncology.  "Our extensive oncology pipeline targets important pathways and specific genetic mutations that can lead to cancer, which we hope will enable us to come up with better therapies, more quickly.  This is part of our commitment to changing the world of cancer care," he added.    

Select studies, as well as the times and locations of the data sessions, are highlighted below.

Cixutumumab (IMC-A12)

  • Abstract # 10004: Oral Abstract Session: Monday, June 6, 2011, 4:15 PM - 4:30 PM
    • Phase II trial of anti-IGF-IR antibody cixutumumab in patients with advanced or metastatic soft tissue sarcoma and Ewing family of tumors.
    • Author/Speaker: P. Schoffski, D. Adkins, J. Y. Blay, T. Gil, A. D. Elias, P. Rutkowski, G. K. Pennock, H. Youssoufian, N. J. Zojwalla, R. Willey, D. O. Grebennik
    • Location: E354a

Ramucirumab (IMC-1121B)

  • Abstract #TPS151: Trials in Progress Poster Session: Monday, June 6, 2011, 8:00 AM - 12:00 PM
    • Randomized phase 2 study of capecitabine with or without ramucirumab (IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or metastatic breast cancer (mBC) previously treated with anthracycline and taxane therapy (CP20-0903/NCT01234402).
    • Author/Speaker: L. T. Vahdat, K. Miller, J. A. Sparano, H. Youssoufian, J. D. Schwartz, S. Nanda, W. Wang, L. Abad, A. Dontabhaktuni, M. D. Rutstein
    • Location: Hall A; Poster Board 42E

Anti-BAFF antibody (LY2127399)

  • Abstract #8012: Oral Abstract Session: Sunday, June 5, 2011, 11:15 AM - 11:30 AM
    • Phase 1 study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously-treated multiple myeloma
    • Author/Speaker: Noopur Raje, Raymond Hohl, Edward Faber, Paul Richardson, Andres Forero, Gary Schiller, Adam Cohen, Susan Carpenter, Damien Cronier, Maksim Pashkevich, James Wooldridge, Kenneth Anderson
    • Location: E354a

Enzastaurin

  • Abstract # 8016: Poster Discussion Session: Saturday, June 4, 2011, 8:00 AM - 12:00 PM
    • Randomized Phase II Study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate and high-risk diffuse large B-cell lymphoma (DLBCL) – Preliminary Analysis
    • Author/Speaker: John D. Hainsworth, Edward R. Arrowsmith, Michael McCleod, Luis E. Fayad, Oday Hamid, Lori Davis, Boris Lin
    • Location: E450b; Poster Board: 2
  • Abstract # 1507: Oral Abstract Session: Monday, June 6, 2011, 5:15 PM - 5:30 PM
    • Final Results of a Chemoprevention Trial with Enzastaurin in Former Smokers
    • Author/Speaker: J. Gray, S. Altiok, M. Alexandrow, F. Walsh, J. Chen, D. Tai, G. Bepler
    • Location: S100bc

TGF-beta molecule (LY2157299)

  • Abstract # 3011: Poster Discussion Session: Saturday, June 4, 2011, 2:00 PM - 6:00 PM
    • First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma.
    • Author/Speaker: Jordi Rodon Ahnert
    • Location: S403; Poster Board #1

P-LLY

This press release contains forward-looking statements about the potential of cixutumumab, ramucirumab, enzastaurin, LY2127399 and LY2157299 and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the products will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson ... offers insurance and financial preparation services, is providing an update on a charitable ... , Rock City Rescue is a locally recognized nonprofit that provides shelter and ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a ... utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the ... a CBD form that can be easily incorporated into liquid products, while reducing costs ...
(Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
Breaking Medicine News(10 mins):